

## Effect of inorganic salts on the inclusion complex formation and solubilizing potency of cyclodextrins

The competition of hydrophobic molecules for the cyclodextrin (CD) cavity is well known and reported in the literature. However, it is not so trivial, how inorganic salts, small cations and anions may affect the inclusion complex formation, and thereby the functional properties of CDs. This topic is recently of particular interest for formulators since there are several granted patents and published patent applications on commercially available CD derivatives with certain intrinsic ion contents (in particular chloride and phosphate), such as US patents [US7635773](#), [US8410077](#), [US9200088](#), [US9493582](#) as well as US patent applications [US2015284479](#) and [US2015045311](#). All these documents highlight that the absence of these ions is specifically favored. On the other hand, the patent disclosing the SBE-BCD-based amiodarone formulation ([US6869939](#)) states that the advantage of using SBE-BCD is that a wider range of buffers was found compatible compared to other known (surfactant-containing) amiodarone-containing liquid formulations. Suitable buffering agents were enumerated such as phosphate and borate. In Example 10 of patent US6869939, a suitable formulation containing amiodarone HCl (50 mg/mL) in a solution containing 114 mM monobasic sodium phosphate and 30% w/v SBE-BCD is illustrating the advantageous use of phosphate ions in a SBE-BCD based formulation.

### Effect of inorganic ions on the complexation with native CDs

In the pioneering work of Mochida et al. (1973) dealing with the effect of inorganic ions on the complex formation with CDs both positive and negative effects were described. The apparent association constant ( $K_{app}$ ) of a complex between  $\beta$ -cyclodextrin (BCD) and an azo dye, Na *p*-(4-hydroxy-1-naphthylazo) benzenesulfonate (HNB) determined by spectrophotometry in a phosphate buffer solution (pH 5.91) increased or decreased in the presence of other salts (Fig. 1). While  $K_{app}$  almost doubled in the presence of potassium sulfate, it decreased to the half or less with KI, KSCN and  $KClO_4$ .






Fig. 1. The apparent association constant of Na HNB azo dye in the presence of various inorganic salts at 0.03 M and 0.3 M concentration in 0.1 M phosphate buffer (data calculated from Mochida et al. 1973)

The decrease of the association constant was attributed to competitive binding between the dye and the inorganic anion. Based on this assumption the order of anions concerning their affinity toward the CD cavity is as follows:



The enhancement of  $K_{app}$ , explained by the decrease of water activity, follows the order of (for the effect of  $\text{PO}_4^{3-}$  see Fig. 2):



Neither increase nor decrease of the association constant of the azo dye/BCD complex was observed with  $\text{KNO}_3$ .

This order was confirmed by polarography and NMR (Taraszewska and Wojcik 1993):  $\text{PF}_6^-$ ,  $\text{ClO}_4^-$  and  $\text{SCN}^-$  were complexed to a high extent, while  $\text{SO}_4^{2-}$ ,  $\text{F}^-$  and  $\text{PO}_4^{3-}/\text{H}_2\text{PO}_4^-$  showed negligible effect.

In the studies of Mochida et al. (1973)  $K_{app}$  increased slightly also with an increase in the concentration of the phosphate buffer (Fig. 2). An order of magnitude enhancement in the concentration of the salt resulted in approx. 20% increase in the association constant.




Fig. 2. The apparent association constant of Na *p*-(4-hydroxy-1-naphthylazo) benzenesulfonate/BCD complex as a function of the concentration of the phosphate buffer (data calculated from Mochida et al. 1973)

Buváry and Barcza (1979) studied the phenolphthalein/BCD complex in various salt solutions (Fig. 3). The apparent stability constant ( $\beta^*$ ) values were calculated by assuming the formation of mixed (phenolphthalein + anions + cations) complexes. It can be seen that certain inorganic anions play crucial role, but also the cations have a slight effect. The most stable mixed complexes are formed with sulfate and chloride ions, while thiocyanate and perchlorate rather compete for the cavity.




Fig. 3. Apparent association constant of mixed phenolphthalein/inorganic anion/inorganic cation complexes with BCD as a function of salts concentration (Buvári and Barcza 1979)

Similar relationships were obtained for benzoic acid and methyl orange BCD complexes (Buvari & Barcza 1989). It was concluded that the changes in water activity are of minor importance, but the formation of real inclusion complexes or the attachment of the anions from outside to the host-guest complex by electrostatic interactions or by hydrogen bonds (mixed complexes) are more conceivable.

Since the review on the complexation of inorganic ions by the native CDs in 1996 (Fenyvesi et al.) summarizing the similar findings for the three native CDs obtained by various experimental techniques including electrochemical methods, polarography and freezing point depression, only a few studies have been published.

Matsui et al. (1997) studied the complexation of inorganic anions by  $\alpha$ -CD (ACD) using NMR. The chaotropic anions (anions disrupting the hydrogen bonding network between water molecules) such as  $\text{Br}^-$ ,  $\text{I}^-$ ,  $\text{SCN}^-$ ,  $\text{N}_3^-$ ,  $\text{ClO}_4^-$ , and  $\text{NO}_3^-$  caused marked shifts in the C(5)-H signals showing that these ions are included in the cavity of ACD. The antichaotropic anions such as  $\text{F}^-$ ,  $\text{HCO}_3^-$ ,  $\text{H}_2\text{PO}_4^-$ ,  $\text{HPO}_4^{2-}$  caused no or very small shifts. Similar, but smaller effects were observed for BCD and GCD.

Yi et al. (1999) investigated some buffer components on the formation constant of 3-hydroxy-2-naphthoic acid/BCD complex using fluorescence competitive inhibition technique. The formation constants for the competing salt/BCD complexation were calculated. It was concluded that only the more lipophilic  $\text{ClO}_4^-$  and  $\text{Cl}^-$  ions were included in the cavity *via* van der Waals and hydrophobic interactions, while  $\text{KF}$ ,  $\text{K}_2\text{SO}_4$ ,  $\text{NaH}_2\text{PO}_4$ ,  $\text{Na}_3\text{PO}_4$ ,  $\text{Na}$  acetate and  $\text{NaHCO}_3$  did not form inclusion complex as the formation constants were negative. These ions are located in the hydrophilic rim formed by the primary hydroxyl groups of CD.

The group of Zughul studied the effect of buffer components on complex formation of various drugs with BCD (Al Omari et al. 2006, 2006a, 2007 and 2009). Celecoxib was the model acidic drug fully ionized at high pH, while unionized at acidic pH and terfenadine the model drug of basic character ionized at acidic pH and unionized at pH 12. Increasing phosphate buffer concentration enhanced the tendency of ionized drugs (celecoxib at high pH and terfenadine at low pH) to complex with BCD as a result of a corresponding decrease in the inherent solubility ( $S_0$ ) of the drug ions (Al Omari et al. 2006a and 2007). On the other hand, increasing phosphate buffer concentration enhanced the complexation of neutral celecoxib by lowering  $S_0$  (solubility without CD), and decreased the solubilization of neutral terfenadine.

### **Effect of inorganic ions on the complexation with CD derivatives**

Similarly to the native CDs the chemical shifts of some  $^1\text{H}$  NMR signals given by mono[6-(1-pyridinio)-6-deoxy]- $\alpha$ -CD in  $\text{D}_2\text{O}$  were significantly changed by the addition of alkali salts of chaotropic anions such as  $\text{Br}^-$ ,  $\text{I}^-$ ,  $\text{SCN}^-$ ,  $\text{N}_3^-$ ,  $\text{ClO}_4^-$ , and  $\text{NO}_3^-$ . However, only small changes in the values of the chemical shifts were brought about by the addition of alkali salts of antichaotropic anions or kosmotropes such as  $\text{F}^-$ ,  $\text{Cl}^-$ ,  $\text{SO}_4^{2-}$ ,  $\text{H}_2\text{PO}_4^-$ ,  $\text{HPO}_4^{2-}$  (Mu et al. 1993).

It was concluded that the chaotropic anions were included within the cavity and attracted the pyridinio group of CD close to the C(6)-H.

The solubility of poorly soluble  $\text{Li}_2\text{CO}_3$  was increased to a large extent in solutions of  $\alpha$ -,  $\beta$ -, and  $\gamma$ -CDs and DIMEB giving  $A_N$  type solubility isotherm (Song & Bai 2009). The binding ability of both D- and L-tryptophan by the CDs was increased effectively by this salt.

Table 1 lists some so far unpublished solubility data of various drugs in aqueous solutions of sulfobutyl BCD (SBE-BCD) in the presence of  $\text{Cl}^-$  and  $\text{PO}_4^{3-}$  with sodium as counter ion. The data show that neither  $\text{Cl}^-$  nor  $\text{PO}_4^{3-}$  exhibited an effect exceeding the experimental error. To perform these experiments, a research grade SBE-BCD sample (prepared by Cyclolab for internal use) containing less than 10 mg/kg intrinsic  $\text{PO}_4^{3-}$  and a commercially available lot of Dexolve (Cyclolab's Betadex Sulfobutyl Ether Sodium), having 538 mg/kg intrinsic  $\text{PO}_4^{3-}$  and less than 0.01% intrinsic  $\text{Cl}^-$  content was used. In this systematic study on the eventual effect of the presence of chloride and phosphate ions on the solubility-enhancing potential, five model drug compounds and spiked solutions of these SBE-BCD samples were used.

Table 1. Solubility data (in 20 w% SBE-BCD (Dexolve), 30 °C. Concentration unit: mg/ml)

	Ziprasidone mesylate trihydrate	Carbamazepine	Voriconazole	Diclofenac Na	Propofol
SBE-BCD $\text{PO}_4^{3-} < 10$ mg/kg $\text{Cl}^- < 0.01$ %	$30 \pm 2$	$9.5 \pm 1.0$	$21 \pm 3$	$34 \pm 2$	$11 \pm 1$
SBE-BCD $\text{PO}_4^{3-} < 10$ mg/kg $\text{Cl}^- = 0.2$ %	$29 \pm 2$	$9.6 \pm 1.0$	$21 \pm 3$	$34 \pm 2$	$12 \pm 1$
SBE-BCD $\text{PO}_4^{3-} = 538$ mg/kg $\text{Cl}^- < 0.01$ %	$30 \pm 2$	$10.4 \pm 1.0$	$18 \pm 3$	$34 \pm 2$	$12 \pm 1$
SBE-BCD $\text{PO}_4^{3-} = 5500$ mg/kg $\text{Cl}^- < 0.01$ %	$31 \pm 2$	$10.0 \pm 1.0$	$18 \pm 3$	$35 \pm 2$	$13 \pm 1$

BCD-bonded silica for solid phase extraction (sample preparation for concentration of the samples before chromatographic analysis) showed reduced efficiency in sorption of various nitrophenols in the presence of various salts, such as  $\text{CaCl}_2$ ,  $\text{NaCl}$ ,  $\text{KCl}$  and  $\text{Na}_2\text{SO}_4$ . The inorganic ions might either occupy the cavity or form steric hindrance at the rim resulting in reduced sorption capacity.

Densely packed monolayers of per-2,3-methylated per-6-thiolated  $\alpha$ -,  $\beta$ -, and  $\gamma$ -cyclodextrins on the hanging mercury drop electrode made possible to study the inclusion of inorganic ions into the monolayer by capacitance measurements (Chamberlain et al. 2000). Whereas the smaller and less well solvated anions  $\text{Cl}^-$ ,  $\text{NO}_3^-$ , and  $\text{ClO}_4^-$  were included in the CD cavities of

these monolayers, the larger and more strongly solvated anions  $F^-$ ,  $SO_4^{2-}$ , and  $H_2PO_4^-$  were excluded. On the contrary to these findings Domi et al. (2011) published that the catalytic effect of ferrocene included in perthio-CD monolayers on gold electrode was inhibited by the presence of some anions ( $SO_4^{2-}$ ,  $NO_3^-$ ,  $HPO_4^{2-}$ ) owing to the competitive complexation of these anions. The association of  $SO_4^{2-}$ ,  $NO_3^-$ ,  $HPO_4^{2-}$  to the monolayer was much stronger than that of  $ClO_4^-$ ,  $Cl^-$ , and  $Br^-$  showing that the surface-bound CDs behave differently compared to solution.

## Conclusions

The effects of salts on the inclusion complex formation depend on several factors:

- CD type (cavity size, substituents type and degree of substitution)
- guest type (charge, affinity to CDs)
- inorganic anions (size, chaotropic property, hydrophobic character)
- inorganic cations (charge, hydrodynamic radius).

The highest effects were seen for native BCD among CD derivatives. The chaotropic anions might interfere with the H-bonding network of the OH groups hence enhancing the solubility of BCD.

The anions might decrease the solubility of the guest molecule (salting out) enhancing its affinity for complexation.

These rules are not valid for CDs bound to surfaces, which bind inorganic anions in such a high extent that sulfate can expel ferrocene out of the cavities.

## References

- Al Omari, M.M., Zughul, M.B., Davies, J.E.D., Badwan, A.A. (2006) Factors contributing to solubility synergism of some basic drugs with beta-cyclodextrin in ternary molecular complexes. *J. Incl. Phenom. Macrocycl. Chem.* 54(3-4), 159–164
- Al Omari, M.M., Zughul, M.B., Davies, J.E.D., Badwan, A.A. (2006a) Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution. *J. Incl. Phenom. Macrocycl. Chem.* 55, 247–254
- Al Omari, M.M., Zughul, M.B., Davies, J.E.D., Badwan, A.A. (2007) Effect of buffer species on the complexation of basic drug terfenadine with beta-cyclodextrin. *J. Incl. Phenom. Macrocycl. Chem.*, 58(3-4), 227–235
- Al Omari, M.M., El-Barghouthi, M.I., Zughul, M.B., Davies, J.E.D., Badwan, A.A. (2009) Dipyridamole/beta-cyclodextrin complexation: effect of buffer species, thermodynamics, and guest-host interactions probed by  $^1H$ -NMR and molecular modeling studies. *J. Incl. Phenom. Macrocycl. Chem.* 64(3-4), 305–315
- Buvari, A., Barcza, L. (1979)  $\beta$ -Cyclodextrin complexes of different type with inorganic compounds. *Inorg. Chim. Acta*, 33(2), L179–L180
- Buvari, A., Barcza, L. (1989) Complex formation of inorganic salts with beta-cyclodextrin. *J. Incl. Phenom. Mol. Recognit. Chem.* 7(3), 379–389

- Chamberlain, R.V., Slowinska, K., Majda, M., Bühlmann, P., Aoki, H., Umezawa, Y. (2000) Electrostatically-induced inclusion of anions in cyclodextrin monolayers on electrodes. *Langmuir* 16 (3), 1388–1396
- Domi, Y., Ikeura, K., Okamura, K., Shimazu, K. (2011) Strong inclusion of inorganic anions into  $\beta$ -cyclodextrin immobilized to gold electrode. *Langmuir* 27, 10580–10586
- Fan, Y., Feng, Y.Q., Da, S.L., Feng, P.Y. (2003) Evaluation of  $\beta$ -cyclodextrin bonded silica as a selective sorbent for the solid-phase extraction of 4-nitrophenol and 2,4-dinitrophenol. *Anal. Sci.* 19, 709–714
- Fenyvesi, E., Szente, L., Russell, N.R., McNamara, M. (1996) Specific guest types. In: *Comprehensive Supramolecular Chemistry* (1996), Volume 3 Cyclodextrins, pp. 305–366. Eds: Szejtli, J., Osa, T. Elsevier, Oxford, UK.
- Matsui, Y., Ono, M., Tokunaga, S. (1997) NMR spectroscopy of cyclodextrin-inorganic anion systems. *Bull. Chem. Soc. Jpn.* 70(3), 535–541
- Mochida, K., Kagita, A., Matsui, Y., Date, Y. (1973) Effects of inorganic salts on the dissociation of a  $\beta$ -cyclodextrin complex with an azo dye in an aqueous solution. *Bull. Chem. Soc. Jpn.* 46(12), 3703–3707
- Mu, P., Okada, T., Iwami, N., Matsui, Y. (1993) Proton NMR response of mono[6-(1-pyridinio)-6-deoxy]- $\alpha$ -cyclodextrin to inorganic anions. *Bull. Chem. Soc. Jpn.* 66(7), 1924–1928
- Song L.X, Bai L. (2009) Old drugs, new tricks: the effect of molecule-ion interactions on the precipitation-dissolution equilibrium of lithium carbonate in aqueous solution and on the chiral recognition of cyclodextrins to D-,L-tryptophan. *J. Phys. Chem. B.* 113(34), 11724–11731.
- Taraszevska J., Wójcik, J. (1993) Complexation of inorganic anions by  $\beta$ -cyclodextrin studied by polarography and  $^1\text{H}$  NMR. *Supramol. Chem.* 2(4), 337–343
- Yi, Z., Zhao, C., Huang, Z., Chen, H., Yu, J. (1999) Investigation of buffer-cyclodextrin systems. *Phys. Chem. Chem. Phys.* 1(3), 441–444
- US7635773, US8410077, US9200088:** Antle, V. (Cydex) (2008) Sulfoalkyl ether cyclodextrin compositions.
- US9493582, US2015284479, US2015045311:** Antle, V. (Cydex) (2012) Alkylated cyclodextrin compositions and processes for preparing and using the same.
- US6869939:** Mosher, G.L., Johnson, K.T., Gayed, A.A. (Cydex) (2012) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin.

**Éva Fenyvesi & István Puskás**

CycloLab Cyclodextrin R&D Laboratory, Ltd.,  
Budapest, HUNGARY

## BIBLIOGRAPHY & KEYWORDS

Agnes, M.; Thanassoulas, A.; Stavropoulos, P.; Nounesis, G.; Miliotis, G.; Miriagou, V.; Athanasiou, E.; Benkovics, G.; Malanga, M.; Yannakopoulou, K.

### **Designed positively charged cyclodextrin hosts with enhanced binding of penicillins as carriers for the delivery of antibiotics: the case of oxacillin**

*Oxacillin, Oxa-1 beta-lactamase, Thioether-substituted- $\beta$ - and  $\gamma$ CD derivatives, Elongated cavity, Cell crossing*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.04.080

Benkovics, G.; Malanga, M.; Fenyvesi, É.

### **The 'Visualized' macrocycles: Chemistry and application of fluorophore tagged cyclodextrins**

*Review, Drug delivery, Fluorescent microscopy, Chemosensing, Photodynamic therapy*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.04.035

Benkovics, G.; Perez-Lloret, M.; Afonso, D.; Darcsi, A.; Béni, S.; Fenyvesi, É.; Malanga, M.; Sortino, S.

### **A Multifunctional $\beta$ -Cyclodextrin-Conjugate Photodelivering Nitric Oxide with Fluorescence Reporting**

*$\beta$ -cyclodextrin conjugate with an anthracene moiety and a nitroaniline derivative, Singlet oxygen, Light, Anticancer and antibacterial effect*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.05.023

Berben, P.; Mols, R.; Brouwers, J.; Tack, J.; Augustijns, P.

### **Gastrointestinal behavior of itraconazole in humans – Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution**

*HPBCD, AP-type phase-solubility diagram, Intraluminal dilution, Solubility-permeability interplay, Precipitation*

International Journal of Pharmaceutics, 2017, 526, 235-243; DOI:10.1016/j.ijpharm.2017.04.057

Blatnik, J. A.; Thatiparti, T. R.; Krpata, D. M.; Zuckerman, S. T.; Rosen, M. J.; von Recum, H. A.

### **Infection Prevention Using Affinity Polymer Coated, Synthetic Meshes in a Pig Hernia Model**

*Cyclodextrin-based polymer crosslinked onto multifilament polyester mesh, Vancomycin, Clearing antibiotic resistant bacteria*

Journal of Surgical Research, 2017, *In Press*; DOI:10.1016/j.jss.2017.05.003

Coviello, V.; Sartini, S.; Quattrini, L.; Baraldi, C.; Gamberini, M. C.; Motta, C. L.

### **Cyclodextrin-based nanosponges for the targeted delivery of the anti-restenotic agent DB103: A novel opportunity for the local therapy of vessels wall subjected to percutaneous intervention**



*Polimerization of  $\beta$ -cyclodextrin with diphenyl carbonate, Cardiovascular diseases, Drug-eluting stent, Local therapy of vessels wall*

European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 276-285; DOI:10.1016/j.ejpb.2017.04.028

Dai, L.; Liu, K.; Wang, L.; Liu, J.; He, J.; Liu, X.; Lei, J.

**Injectable and thermosensitive supramolecular hydrogels by inclusion complexation between binary-drug loaded micelles and  $\alpha$ -cyclodextrin**

*8-Arm-polyethylene glycol, Betulinic acid, Hydroxycamptothecin*

Materials Science and Engineering: C, 2017, 76, 966-974; DOI:10.1016/j.msec.2017.03.151

Hu, J.-J.; Lei, Q.; Peng, M.-Y.; Zheng, D.-W.; Chen, Y.-X.; Zhang, X.-Z.

**A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem**

*ROS-triggered self-accelerating drug release, ROS-cleavable thioketal (TK) linker, Mesoporous silica nanoparticle, Doxorubicin,  $\alpha$ -tocopheryl succinate*

Biomaterials, 2017, 128, 136-146; DOI:10.1016/j.biomaterials.2017.03.010

Huang, D.; Tang, Z.; Peng, Z.; Lai, C.; Zeng, G.; Zhang, C.; Xu, P.; Cheng, M.; Wan, J.; Wang, R.

**Fabrication of water-compatible molecularly imprinted polymer based on  $\beta$ -cyclodextrin modified magnetic chitosan and its application for selective removal of bisphenol A from aqueous solution**

*Selective adsorption, Surface-imprinting, Water-compatible binding sites*

Journal of the Taiwan Institute of Chemical Engineers, 2017, *In Press*; DOI:10.1016/j.jtice.2017.04.030

Jiang, J.; Zhang, Y.; Peng, K.; Wang, Q.; Hong, X.; Li, H.; Fan, G.; Zhang, Z.; Gong, T.; Sun, X.

**Combined delivery of a TGF- $\beta$  inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy**

*Transforming growth factor- $\beta$ ,  $\beta$ -cyclodextrin-PEI, Melanoma*

Acta Biomaterialia, 2017, *In Press*; DOI:10.1016/j.actbio.2017.05.009

Jin, W.; Wang, Q.; Wu, M.; Li, Y.; Tang, G.; Ping, Y.; Chu, P. K.

**Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy**

*Nanomedicine, Organic-inorganic hybrid materials, Adamantane-modified doxorubicin, Polyethylenimine-crosslinked- $\gamma$ -cyclodextrin, Simultaneous delivery of doxorubicin and siRNA*

Biomaterials, 2017, 129, 83-97; DOI:10.1016/j.biomaterials.2017.03.020

Li, X.; Li, J.; Liu, Y.; Zhang, X.; Chen, J.

**A sensitive electrochemical immunosensor for prion detection based on poly- $\beta$ -cyclodextrin/gold nanoparticles/glassy carbon electrode**

*Blocking the electron transfer channel, Diagnosis of prion diseases*

Sensors and Actuators B: Chemical, 2017, 250, 1-7; DOI:10.1016/j.snb.2017.04.101

Loftsson, T.; Stefánsson, E.

**Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye**

*Aggregates, Microparticles, Nanoparticles, Permeation, Dorzolamide and dexamethasone*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.04.010

Lu, Y.; Zou, H.; Yuan, H.; Gu, S.; Yuan, W.; Li, M.

**Triple stimuli-responsive supramolecular assemblies based on host-guest inclusion complexation between  $\beta$ -cyclodextrin and azobenzene**

*Host polymer  $\beta$ -cyclodextrin-poly[(2-(2-methoxyethoxy)ethylmethacrylate)-co-oligo(ethylene glycol) methacrylate] [ $\beta$ -CD-P(MEO2MA-co-OEGMA)], Guest polymer poly( $\epsilon$ -caprolactone)-SS-poly(ethylene glycol) with azobenzene group at one end, Micelles*

European Polymer Journal, 2017, 91, 396-407; DOI:10.1016/j.eurpolymj.2017.04.028

Martínez-Negro, M.; Caracciolo, G.; Palchetti, S.; Pozzi, D.; Capriotti, A.; Cavaliere, C.; Laganà, A.; Mellet, C. O.; Benito, J.; Fernández, J. G.; Aicart, E.; Junquera, E.

**Biophysics and protein corona analysis of Janus cyclodextrin-DNA nanocomplexes. Efficient cellular transfection on cancer cells**

*CDplexes, Effective charge ratio, Protein corona for targeted gene delivery, Multilamellar phases*

Biochimica et Biophysica Acta (BBA)-General Subjects, 2017, *In Press*; DOI:10.1016/j.bbagen.2017.03.010

Ragavan, K.; Rastogi, N. K.

**$\beta$ -Cyclodextrin capped graphene-magnetite nanocomposite for selective adsorption of Bisphenol-A**

*BCD conjugated to  $Fe_3O_4$  nanoparticles embedded on graphene, Nano-adsorbent, Superparamagnetic property*

Carbohydrate Polymers, 2017, 168, 129-137; DOI:10.1016/j.carbpol.2017.03.045

Sohajda, T.; Fábíán, Á.; Tuza, K.; Malanga, M.; Benkovics, G.; Fülesdi, B.; Tassonyi, E.; Szente, L.

**Design and evaluation of artificial receptors for the reversal of neuromuscular block**

*Sugammadex, Capillary electrophoresis screening, Carboxymethylated and sulfobutylated gamma-cyclodextrin derivatives, Neurological agents, Animal study*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.03.060

Tian, Z.; Si, L.; Meng, K.; Zhou, X.; Zhang, Y.; Zhou, D.; Xiao, S.

**Inhibition of influenza virus infection by multivalent pentacyclic triterpene-functionalized per-O-methylated cyclodextrin conjugates**

*Hemagglutinin, Multivalent effect, Disrupting influenza HA protein-host receptor protein interaction*

European Journal of Medicinal Chemistry, 2017, 134, 133-139; DOI:10.1016/j.ejmech.2017.03.087

Varan, C.; Wickström, H.; Sandler, N.; Aktaş, Y.; Bilensoy, E.

**Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration**

*Cidofovir, Nanoparticle, Paclitaxel, HPV-related cervical cancer treatment*

International Journal of Pharmaceutics, 2017, *In Press*; DOI:10.1016/j.ijpharm.2017.04.036

Vollrath, M.; Engert, J.; Winter, G.

**Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants**

*HPBCD, Lipid implants, Protein stability, Ranibizumab, Monoclonal antibody*

European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 244-255; DOI:10.1016/j.ejpb.2017.04.017

Xiong, Q.; Cui, M.; Bai, Y.; Liu, Y.; Liu, D.; Song, T.

**A supramolecular nanoparticle system based on  $\beta$ -cyclodextrin-conjugated poly-L-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma**

*Doxorubicin, "core-shell" structure, Receptor-mediated endocytosis*

Colloids and Surfaces B: Biointerfaces, 2017, 155, 93-103; DOI:10.1016/j.colsurfb.2017.04.008

Xuan, H.; Ren, J.; Wang, X.; Zhang, J.; Ge, L.

**Flame-retardant, non-irritating and self-healing multilayer films with double-network structure**

*Layer-by-layer (LbL) assembly, Poly (acrylic acid)-adamantanamine/ammonium polyphosphate-cross-poly (ethylenimine)- $\beta$ -cyclodextrin*

Composites Science and Technology, 2017, 145, 15-23; DOI:10.1016/j.compscitech.2017.03.038

Zeid, A. M.; Kaji, N.; Nasr, J. J. M.; Belal, F. F.; Baba, Y.; Walash, M. I.

**Stacking-cyclodextrin-microchip electrokinetic chromatographic determination of gabapentinoid drugs in pharmaceutical and biological matrices**

*$\beta$ -Cyclodextrin, Pharmaceutical dosage forms, Biological fluids*

Journal of Chromatography A, 2017, 1503, 65-75; DOI:10.1016/j.chroma.2017.04.049



Edited and produced by: CYCLOLAB

Homepage: [www.cyclolab.hu](http://www.cyclolab.hu)

H-1525 P.O. 435, Budapest,  
Hungary

Tel.: (+361)347-6060

Fax.: (+361)347-6068

e-mail: [cyclolab@cyclolab.hu](mailto:cyclolab@cyclolab.hu)